Price$11.31-0.08 (-0.70%)
01:30 PM07:45 PM
News · 26 weeks33+100%
2026-01-182026-07-12
Mix990d
- SEC Filings3(33%)
- Earnings2(22%)
- Other2(22%)
- Insider1(11%)
- Leadership1(11%)
Latest news
25 items- PRCORE LABORATORIES ANNOUNCES TIMING OF SECOND QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALLHOUSTON, June 30, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EDT on July 30, 2026. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 29, 2026, and may be accessed through the Company's website at www.corelab.com/investors.To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast
- SECSEC Form 11-K filed by Core Laboratories Inc.11-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- PRGulfport Energy and Mobility Global Set to Join S&P SmallCap 600NEW YORK, June 26, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: Gulfport Energy Corp. (NYSE:GPOR) will replace Select Medical Holdings Corp. (NYSE:SEM) effective prior to the opening of trading on Wednesday, July 1. Select Medical Holdings is being acquired in a deal expected to be completed soon, pending final closing conditions.Mobility Global Inc. (NYSE:MBGL) will replace Core Laboratories Inc. (NYSE:CLB) effective prior to the opening of trading on Thursday, July 2. S&P 500 constituent S&P Global Inc. (NYSE:SPGI) is spinning off Mobility Global in a transaction expected to be completed July 1. Core Laboratories is no longer represen
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
- SECSEC Form SD filed by Core Laboratories Inc.SD - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECCore Laboratories Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- INSIDERSVP, Gen Counsel & Secretary Tattoli Mark Damian covered exercise/tax liability with 97 shares and converted options into 250 shares (SEC Form 4)4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- PRCORE LAB REPORTS FIRST QUARTER 2026 RESULTSREVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEARGAAP LOSS PER SHARE OF $0.02; EPS EX-ITEMS OF $0.06, DOWN 72% SEQUENTIALLY AND 58% YEAR-OVER-YEARFREE CASH FLOW OF $0.5 MILLIONNET DEBT INCREASED BY $3.9 MILLION; LEVERAGE RATIO AT 1.20COMPANY REPURCHASED 51,781 SHARES OF COMMON STOCK, FOR $0.9 MILLION AGGREGATE PURCHASE PRICECOMPANY ANNOUNCES Q2 2026 QUARTERLY DIVIDENDHOUSTON, April 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported first quarter 2026 revenue of $121,800,000. Core's operating income was $1,900,0
- SECCore Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- INSIDERSEC Form 4 filed by Murray Katherine4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Anastasio Curt4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Klingensmith Harvey Robert4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Temeng Kwaku4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Martinovich Robert F4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- INSIDERSEC Form 4 filed by Carnes Martha Z.4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
- SECSEC Form DEFA14A filed by Core Laboratories Inc.DEFA14A - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECSEC Form DEF 14A filed by Core Laboratories Inc.DEF 14A - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
- PRCORE LAB ANNOUNCES IMPACT OF THE MIDDLE EAST CONFLICT TO FIRST QUARTER 2026 GUIDANCEFIRST QUARTER 2026 EARNINGS WEBCAST AT 7:30 A.M. CDT / 8:30 A.M. EDT ON APRIL 30, 2026HOUSTON, March 23, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority.At this time, due to regional instability, including client-driven project delays, travel const
- SECCore Laboratories Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECSEC Form 10-K filed by Core Laboratories Inc.10-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECAmendment: Core Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K/A - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECCore Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECSEC Form NT 10-K filed by Core Laboratories Inc.NT 10-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Core Laboratories Inc.SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
CLB FAQ
8 questionsWhat does Core Laboratories Inc. do?
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and petroleum products; and...Where does CLB stock trade?
Core Laboratories Inc. (CLB) is listed on NYSE.What sector and industry is CLB in?
Core Laboratories Inc. operates in the Energy sector, Oilfield Services/Equipment industry.When did Core Laboratories Inc. go public?
Core Laboratories Inc. (CLB) completed its IPO in 2023.Does CLB pay a dividend?
CLB's most recent ex-dividend date was 2026-05-11 with a cash dividend of $0.01 per share. No future ex-date is on file yet.What are analysts saying about CLB?
Core Laboratories Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral with a $1600.00 price target on 2025-03-12. Recent price targets range from $1600.00 to $3000.00.What companies are similar to CLB?
Notable peers in the same industry include SLB (SLB Limited), HAL (Halliburton Company), SHLX (Shell Midstream Partners L.P.), WBI (WaterBridge Infrastructure LLC), OII (Oceaneering International Inc.). Compare CLB side-by-side with any of them on Quantisnow.How can I track CLB on Quantisnow?
Quantisnow aggregates Core Laboratories Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLB to receive live email and push alerts on every new disclosure.